Verastem presents two-year follow-up data for ovarian cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the S
April 10, 2026 7:00 AM EDTPatients in the Phase 2 RAMP 201 clinical trial demonstrated sustained clinical benefits across multiple efficacy measures highlighting durability of response with a median follow-up of two years
52% of patients with a KRAS mutation and 30% of patients with KRAS wild-type recurrent LGSOC remained on therapy for more than one year
After two years of follow-up, the combination therapy continued to demonstrate a well-tolerated safety profile, with no new safety signals and a low discontinuation rate due to adverse events
Poster presentation of new exposure response... More
